[EN] HUMAN PLASMA KALLIKREIN INHIBITORS<br/>[FR] INHIBITEURS DE LA KALLICRÉINE PLASMATIQUE HUMAINE
申请人:BIOCRYST PHARM INC
公开号:WO2015134998A1
公开(公告)日:2015-09-11
Disclosed are compounds of formula (I), as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.
aerospace materials, for example, Kapton®. The arylation of aromatic diamines with arylhydrazine hydrochlorides was achieved in reasonable yields. This new and simple reaction occurred at room temperature in air using an inexpensive base. This transformation seems to proceed via a homolyticaromaticsubstitution (HAS) mechanism. The synthesized aromatic diamines are used as raw materials for polyimides, including
[EN] 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF<br/>[FR] COMPOSÉS DE PHÉNYLAMIDINE 3-SUBSTITUÉS, LEUR PRÉPARATION ET LEUR UTILISATION
申请人:PI INDUSTRIES LTD
公开号:WO2020148617A1
公开(公告)日:2020-07-23
The present invention disclosed 3-substituted phenylamidine compounds of general formula (I), wherein R1, R2, R3, R4, R4a, R4b, A and E have the same meanings as defined in description. The present invention further discloses methods for their preparation and use of the compounds of general formula (I) as a crop protection agent.
MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, AND LIGHTING DEVICE
申请人:JNC Corporation
公开号:US20150097162A1
公开(公告)日:2015-04-09
Provided is an organic electroluminescent element which has improved driving voltage and improved current efficiency. An organic electroluminescent element having the above-mentioned improved characteristics is provided by using, as a material for organic electroluminescent elements, a polycyclic aromatic compound in which a nitrogen atom and another heteroatom or a metal atom (X) are adjacent to each other in a non-aromatic ring.
A platelet aggregation inhibitor comprising a quinolone derivative or a pharmaceutically acceptable salt thereof as an active ingredient, and a novel quinolone derivative or a pharmaceutically acceptable salt thereof useful as a platelet aggregation inhibitor.